• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $CVET

    Covetrus Inc.

    Subscribe to $CVET
    $CVET
    Other Pharmaceuticals
    Health Care

    Covetrus, Inc., together with its subsidiaries, operates as an animal-health technology and services company. It engages in the sale of animal-health consumable products, including proprietary and Covetrus branded products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, parasiticides, and vitamins and supplements to wholesale and retail customers. The company also offers value-added solutions that include, inventory management and e-commerce, as well as continuing education services for practitioners. In addition, it provides practice management software systems for veterinary practitioners and animal-health clinics, client communication services, reminders, data backup services, and hardware sales and support services. Further, the company engages in the distribution of finished goods pharmacy and specialty pharmaceutical compounding products, as well as shipping, manufacturer incentives, service fees, and data integration and support services. It serves animal-health and veterinary practices, and clinics in the companion-animal and equine markets primarily in North America, Europe, and the Asia Pacific. The company was formerly known as HS Spinco, Inc. Covetrus, Inc. was incorporated in 2018 and is headquartered in Portland, Maine.

    IPO Year:

    Exchange: NASDAQ

    Website: covetrus.com

    Recent Analyst Ratings for Covetrus Inc.

    DatePrice TargetRatingAnalyst
    6/13/2022$22.00Buy → Hold
    Stifel
    5/23/2022Outperform → Mkt Perform
    Raymond James
    11/18/2021$19.00Equal-Weight
    Morgan Stanley
    11/5/2021$37.00 → $27.00Outperform
    Raymond James
    8/9/2021$46.00 → $38.00Overweight
    Barclays
    8/6/2021$38.00 → $37.00Outperform
    Raymond James
    8/5/2021$29.00Neutral
    Credit Suisse
    7/12/2021$30.00Neutral → Buy
    Guggenheim
    See more ratings

    Covetrus Inc. Financials

    Live finance-specific insights

    See more
    • Covetrus Announces Financial Results for Second Quarter of 2022

      Second quarter 2022 net sales of $1.22 billion, an increase of 2% year-over-year; GAAP net loss attributable to Covetrus of $(4) million Non-GAAP organic net sales growth of 5% year-over-year Non-GAAP adjusted EBITDA was flat year-over-year at $66 million, including a $2 million year-over-year headwind from the strengthening of the U.S. Dollar First half 2022 net sales of $2.37 billion, an increase of 3% year-over-year; GAAP net loss attributable to Covetrus of $(6) million Non-GAAP organic net sales growth of 6% year-over-year Non-GAAP adjusted EBITDA increased 5% year-over-year to $129 million, including a $4 million year-over-year headwind from the strengthening of the U.S.

      8/4/22 8:00:00 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • Covetrus Announces First Quarter 2022 Earnings Release Date and Conference Call Information

      Covetrus® (NASDAQ:CVET), a global leader in animal-health technology and services, announced today that it will release first quarter 2022 results after the market closes on Thursday, May 5, 2022. Following the release, the Company will hold a conference call at 4:30 PM ET, during which Ben Wolin, president and chief executive officer, and Matthew Foulston, executive vice president and chief financial officer, will review the results. To access the live webcast of the conference call and the corresponding slide presentation, individuals can register at our Investor Relations site: https://ir.covetrus.com/investors/events-and-presentations. An archived edition of the conference call will be

      4/29/22 8:00:00 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • Covetrus Announces Financial Results for Fourth Quarter and Full-Year of 2021

      Fourth quarter 2021 net sales of $1.12 billion, unchanged year-over-year; GAAP net loss attributable to Covetrus of $(3) million Non-GAAP organic net sales growth of 2% year-over-year Non-GAAP adjusted EBITDA increased 13% year-over-year to $63 million Full-year 2021 net sales of $4.58 billion, an increase of 5% year-over-year; GAAP net loss attributable to Covetrus of $(54) million Non-GAAP organic net sales growth of 5% year-over-year Non-GAAP adjusted EBITDA increased 8% year-over-year to $244 million 2022 non-GAAP organic net sales growth guidance of 7% to 8% and non-GAAP adjusted EBITDA guidance in the range of $270 million to $280 million Covetrus® (NASDAQ:CVET), a

      2/24/22 4:01:00 PM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • Covetrus Announces Fourth Quarter and Full-Year 2021 Earnings Release Date and Conference Call Information

      Covetrus (NASDAQ:CVET), a global leader in animal-health technology and services, announced today that it will release fourth quarter and full-year 2021 results after the market closes on Thursday, February 24, 2022. Following the release, the Company will hold a conference call at 4:30 PM ET, during which Covetrus president and chief executive officer, Benjamin Wolin, and executive vice president and chief financial officer, Matthew Foulston, will review the fourth quarter and full-year 2021 results. To access the live webcast of the conference call, individuals can visit the Investor Relations page of the Covetrus website: https://ir.covetrus.com/investors/events-and-presentations. An ar

      2/17/22 8:00:00 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • Henry Schein Reports Record Non-GAAP Fourth-Quarter and Full-Year 2021 Financial Results

      Fourth-quarter total net sales of $3.3 billion up 5.2% compared with prior-year Fourth-quarter GAAP diluted EPS from continuing operations of $1.05 compared with prior-year GAAP diluted EPS from continuing operations of $0.99 Fourth-quarter non-GAAP diluted EPS from continuing operations of $1.07 compared with prior-year non-GAAP diluted EPS from continuing operations of $1.00 Introduces full-year 2022 GAAP diluted EPS guidance to be $4.75 to $4.91, reflecting growth of 7% to 10% over 2021 GAAP diluted EPS and growth of 5% to 9% over 2021 non-GAAP diluted EPS Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical p

      2/15/22 6:30:00 AM ET
      $CVET
      $HSIC
      Other Pharmaceuticals
      Health Care
      Medical Specialities
    • Covetrus Announces Financial Results for Third Quarter of 2021

      Third quarter GAAP net sales of $1.16 billion, an increase of 3% year-over-year; non-GAAP organic net sales increased 3% year-over-year Third quarter GAAP net loss attributable to Covetrus of $(4) million versus GAAP net loss attributable to Covetrus of $(35) million in the prior year period; third quarter non-GAAP adjusted net income of $31 million, an increase of 3% year-over-year Third quarter non-GAAP adjusted EBITDA of $58 million, a decline of 2% year-over-year; non-GAAP adjusted EBITDA margin decreased 20 bp year-over-year to 5.0% Full-year 2021 non-GAAP organic net sales growth guidance of 5% to 6% and non-GAAP adjusted EBITDA guidance range of $245 million to $255 million

      11/4/21 4:01:00 PM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • Henry Schein Reports Record Third-Quarter 2021 Financial Results From Continuing Operations

      Total net sales of $3.2 billion up 11.9% versus prior year GAAP diluted EPS from continuing operations of $1.15 versus prior-year GAAP diluted EPS from continuing operations of $0.99 Non-GAAP diluted EPS from continuing operations of $1.10 versus prior-year non-GAAP diluted EPS from continuing operations of $1.03 Increases 2021 guidance for non-GAAP diluted EPS from continuing operations to a range of $4.27 to $4.35 Introduces preliminary guidance for 2022 non-GAAP diluted EPS from continuing operations reflecting mid to high single-digit growth over 2021 guidance for non-GAAP diluted EPS from continuing operations Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of

      11/2/21 6:30:00 AM ET
      $CVET
      $HSIC
      Other Pharmaceuticals
      Health Care
      Medical Specialities
    • Covetrus Announces Third Quarter 2021 Earnings Release Date and Conference Call Information

      Covetrus® (NASDAQ:CVET), a global leader in animal-health technology and services, announced today that it will release third quarter 2021 results after the market closes on Thursday, November 4, 2021. Following the release, the Company will hold a conference call at 4:30 PM ET, during which Ben Wolin, president and chief executive officer, and Matthew Foulston, executive vice president and chief financial officer, will review the results. To access the live webcast of the conference call and the corresponding slide presentation, individuals can register at our Investor Relations site: https://ir.covetrus.com/investors/events-and-presentations. An archived edition of the conference call wi

      10/26/21 8:30:00 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • Covetrus Announces Financial Results for Second Quarter of 2021

      Second quarter GAAP net sales of $1.19 billion, an increase of 16% year-over-year; non-GAAP organic net sales increased 12% year-over-year Second quarter GAAP net loss attributable to Covetrus of $31 million versus GAAP net income of $54 million in the prior year period; second quarter non-GAAP adjusted net income of $35 million, an increase of 17% year-over-year Second quarter non-GAAP adjusted EBITDA of $66 million, an increase of 5% year-over-year; non-GAAP adjusted EBITDA margin decreased 50 bp year-over-year to 5.6% Full-year 2021 non-GAAP adjusted EBITDA guidance range of $245 million to $255 million remains unchanged Covetrus® (NASDAQ:CVET), a global leader in animal-hea

      8/5/21 4:05:00 PM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • Henry Schein Reports Record Second-Quarter 2021 Financial Results From Continuing Operations

      Total net sales of $3.0 billion up 76.2% versus prior year and up 21.2% versus 2019 GAAP diluted EPS from continuing operations of $1.10 versus prior-year GAAP loss per diluted share from continuing operations of $0.08 Non-GAAP diluted EPS from continuing operations of $1.11 versus prior-year non-GAAP diluted EPS from continuing operations of $0.00 Reflecting strong first-half financial results, raises guidance for 2021 non-GAAP diluted EPS from continuing operations to be at or above $3.85, representing a floor for fiscal 2021 Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported re

      8/3/21 6:30:00 AM ET
      $HSIC
      $CVET
      Medical Specialities
      Health Care
      Other Pharmaceuticals

    Covetrus Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Covetrus downgraded by Stifel with a new price target

      Stifel downgraded Covetrus from Buy to Hold and set a new price target of $22.00

      6/13/22 7:15:59 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • Covetrus downgraded by Raymond James

      Raymond James downgraded Covetrus from Outperform to Mkt Perform

      5/23/22 7:13:08 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • Morgan Stanley initiated coverage on Covetrus with a new price target

      Morgan Stanley initiated coverage of Covetrus with a rating of Equal-Weight and set a new price target of $19.00

      11/18/21 8:28:56 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • Raymond James reiterated coverage on Covetrus with a new price target

      Raymond James reiterated coverage of Covetrus with a rating of Outperform and set a new price target of $27.00 from $37.00 previously

      11/5/21 10:25:49 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • Barclays reiterated coverage on Covetrus with a new price target

      Barclays reiterated coverage of Covetrus with a rating of Overweight and set a new price target of $38.00 from $46.00 previously

      8/9/21 8:58:58 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • Raymond James reiterated coverage on Covetrus with a new price target

      Raymond James reiterated coverage of Covetrus with a rating of Outperform and set a new price target of $37.00 from $38.00 previously

      8/6/21 12:08:52 PM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • Credit Suisse resumed coverage on Covetrus with a new price target

      Credit Suisse resumed coverage of Covetrus with a rating of Neutral and set a new price target of $29.00

      8/5/21 6:19:56 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • Covetrus upgraded by Guggenheim with a new price target

      Guggenheim upgraded Covetrus from Neutral to Buy and set a new price target of $30.00

      7/12/21 7:23:35 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • Raymond James reiterated coverage on Covetrus with a new price target

      Raymond James reiterated coverage of Covetrus with a rating of Outperform and set a new price target of $39.00 from $31.00 previously

      3/8/21 8:22:43 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • Raymond James reiterated coverage on Covetrus with a new price target

      Raymond James reiterated coverage of Covetrus with a rating of Outperform and set a new price target of $39.00 from $31.00 previously

      3/2/21 7:22:03 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care

    Covetrus Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Cd&R Investment Associates Ix, Ltd. disposed of 33,670,541 shares

      4 - COVETRUS, INC. (0001752836) (Issuer)

      10/13/22 11:44:56 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • SEC Form 4: Helton Sandra L returned 38,095 shares to the company, closing all direct ownership in the company

      4 - COVETRUS, INC. (0001752836) (Issuer)

      10/13/22 11:08:02 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • SEC Form 4: Laskawy Philip A returned 15,064 shares to the company, closing all direct ownership in the company

      4 - COVETRUS, INC. (0001752836) (Issuer)

      10/13/22 11:07:42 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • SEC Form 4: Foulston Matthew J. returned 95,079 shares to the company, closing all direct ownership in the company

      4 - COVETRUS, INC. (0001752836) (Issuer)

      10/13/22 11:07:23 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • SEC Form 4: Ellinger Deborah G returned 28,459 shares to the company, closing all direct ownership in the company

      4 - COVETRUS, INC. (0001752836) (Issuer)

      10/13/22 11:07:02 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • SEC Form 4: Manoff Mark Jeffrey returned 26,595 shares to the company, closing all direct ownership in the company

      4 - COVETRUS, INC. (0001752836) (Issuer)

      10/13/22 11:06:40 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • SEC Form 4: Malenfant Matthew returned 84,304 shares to the company, closing all direct ownership in the company

      4 - COVETRUS, INC. (0001752836) (Issuer)

      10/13/22 11:05:29 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • SEC Form 4: Kidd Rebecca Ann returned 20,028 shares to the company, closing all direct ownership in the company

      4 - COVETRUS, INC. (0001752836) (Issuer)

      10/13/22 11:05:50 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • SEC Form 4: Wolin Benjamin returned 198,711 shares to the company, closing all direct ownership in the company

      4 - COVETRUS, INC. (0001752836) (Issuer)

      10/13/22 11:06:19 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • SEC Form 4: Wraight Georgina returned 95,406 shares to the company, closing all direct ownership in the company

      4 - COVETRUS, INC. (0001752836) (Issuer)

      10/13/22 11:04:46 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care

    Covetrus Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Covetrus Inc. (Amendment)

      SC 13D/A - COVETRUS, INC. (0001752836) (Subject)

      10/13/22 11:50:30 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13D/A filed by Covetrus Inc. (Amendment)

      SC 13D/A - COVETRUS, INC. (0001752836) (Subject)

      5/25/22 12:15:30 PM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13D/A filed by Covetrus Inc. (Amendment)

      SC 13D/A - COVETRUS, INC. (0001752836) (Subject)

      5/20/22 8:00:28 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed by Covetrus Inc. (Amendment)

      SC 13G/A - COVETRUS, INC. (0001752836) (Subject)

      2/14/22 2:34:54 PM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed by Covetrus Inc. (Amendment)

      SC 13G/A - COVETRUS, INC. (0001752836) (Subject)

      2/10/22 11:18:29 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed by Covetrus Inc. (Amendment)

      SC 13G/A - COVETRUS, INC. (0001752836) (Subject)

      2/9/22 3:43:33 PM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13G filed by Covetrus Inc.

      SC 13G - COVETRUS, INC. (0001752836) (Subject)

      2/4/22 9:15:24 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed by Covetrus Inc. (Amendment)

      SC 13G/A - COVETRUS, INC. (0001752836) (Subject)

      1/26/22 8:18:58 PM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed by Covetrus Inc. (Amendment)

      SC 13G/A - COVETRUS, INC. (0001752836) (Subject)

      1/25/22 11:15:50 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13G filed

      SC 13G - COVETRUS, INC. (0001752836) (Subject)

      2/16/21 12:24:00 PM ET
      $CVET
      Other Pharmaceuticals
      Health Care

    Covetrus Inc. SEC Filings

    See more
    • SEC Form 15-12G filed by Covetrus Inc.

      15-12G - COVETRUS, INC. (0001752836) (Filer)

      10/24/22 11:12:59 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • SEC Form S-8 POS filed by Covetrus Inc.

      S-8 POS - COVETRUS, INC. (0001752836) (Filer)

      10/13/22 11:19:58 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13E3/A filed by Covetrus Inc. (Amendment)

      SC 13E3/A - COVETRUS, INC. (0001752836) (Subject)

      10/13/22 11:17:50 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • Covetrus Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

      8-K - COVETRUS, INC. (0001752836) (Filer)

      10/13/22 11:17:04 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • SEC Form 25-NSE filed by Covetrus Inc.

      25-NSE - COVETRUS, INC. (0001752836) (Subject)

      10/13/22 8:56:26 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • Covetrus Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - COVETRUS, INC. (0001752836) (Filer)

      10/11/22 4:37:55 PM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • Covetrus Inc. filed SEC Form 8-K: Other Events

      8-K - COVETRUS, INC. (0001752836) (Filer)

      10/3/22 5:09:44 PM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13E3/A filed by Covetrus Inc. (Amendment)

      SC 13E3/A - COVETRUS, INC. (0001752836) (Subject)

      9/12/22 9:36:37 PM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • SEC Form DEFM14A filed by Covetrus Inc.

      DEFM14A - COVETRUS, INC. (0001752836) (Filer)

      9/12/22 9:33:02 PM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • SEC Form CT ORDER filed by Covetrus Inc.

      CT ORDER - COVETRUS, INC. (0001752836) (Filer)

      9/6/22 2:21:40 PM ET
      $CVET
      Other Pharmaceuticals
      Health Care

    Covetrus Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Semrush Strengthens Customer Focus with Appointment of Veronique Montreuil as Chief Customer and Data Officer

      Semrush (NYSE:SEMR), a leading online visibility management SaaS platform, is pleased to announce that Veronique Montreuil joins the executive team as Chief Customer and Data Officer. With over 20 years of experience in customer success and customer experience, Veronique brings a wealth of expertise to enhance customer relationships and drive growth. In her most recent role as Head of Technology Sales and Customer Success at Covetrus (NASDAQ:CVET), Veronique led a team of 275 professionals, driving operational efficiency, fostering deep customer relationships, and optimizing customer value through strategic initiatives and process improvements. She held prior roles at companies INAP (NASD

      8/8/24 9:00:00 AM ET
      $SEMR
      $CVET
      Computer Software: Prepackaged Software
      Technology
      Other Pharmaceuticals
      Health Care
    • Covetrus Names Michelle Bonfilio as Chief People Officer

      Covetrus® (NASDAQ:CVET), a global leader in animal-health technology and services, today announced the appointment of Michelle Bonfilio as Chief People Officer, reporting to Ben Wolin, President and Chief Executive Officer at Covetrus. In this role, Bonfilio will oversee the human resources and communications organizations and help shape the culture of the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220926005710/en/Michelle Bonfilio (Photo: Business Wire) "Michelle has a proven track record of empowering teams to achieve results, driving an inclusive culture and aligning purpose to the work employees do each day," sai

      9/26/22 4:00:00 PM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • Covetrus Names Margie B. Pritchard General Counsel

      Covetrus® (NASDAQ:CVET), a global leader in animal-health technology and services, today announced the appointment of Margie B. Pritchard as General Counsel and Corporate Secretary, reporting to Ben Wolin, President and Chief Executive Officer (CEO) at Covetrus. Prior to being named as General Counsel, Pritchard most recently served as Vice President, Deputy Counsel at Covetrus, where she was responsible for corporate and board governance, public reporting, advising investor relations, employment matters including compensation, and providing general legal counsel to executive management. "Margie has been serving as Interim General Counsel since December 2021, and we are thrilled to have h

      8/26/22 8:00:00 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • Covetrus Announces Retirement of Matthew Foulston

      Covetrus® (NASDAQ:CVET), a global leader in animal-health technology and services, today announced that Matthew Foulston, the Company's Executive Vice President and Chief Financial Officer, has informed the company that he will be retiring from the company effective December 31, 2022. Foulston's role at Covetrus caps off a strong career in which he has led technical, strategic and operational finance teams within a broad range of manufacturing, distribution and automotive companies. Since joining Covetrus in 2020, Foulston's leadership and depth of experience served the company well. "Matthew is a strong financial partner to our business, our leadership, our Board, and me. Plus, he's a gre

      8/11/22 4:05:00 PM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • Covetrus Taps César França as President, Global Proprietary Brands

      Long-time Nestlé S.A. executive to manage global growth for Covetrus portfolio Covetrus® (NASDAQ:CVET), a global leader in animal-health technology and services, today announced the appointment of César França as President, Global Proprietary Brands. França will lead the companywide development and management of Covetrus' global proprietary brand portfolio, including the current Covetrus, Kruuse, Vi, Roadrunner Pharmacy, and Calibra brands. The company will rely on his vision and expertise to develop categories, build strategic partnerships, and identify external growth opportunities. França brings more than 25 years of leadership and experience in brand development and management, marke

      1/26/22 9:00:00 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • Covetrus Appoints New Chief Accounting Officer

      Drew Coxhead brings deep accounting experience to support Covetrus' transformation Covetrus®(NASDAQ:CVET), a global leader in animal-health technology and services, announced today that Drew Coxhead will be appointed as vice president, corporate controller and chief accounting officer effective August 16, 2021. In this role, Mr. Coxhead will be responsible for Covetrus' global accounting function, filings with the Securities and Exchange Commission and financial reporting systems. Mr. Coxhead will replace Laura Phillips, who announced in April her intent to retire from Covetrus on August 15, 2021. This press release features multimedia. View the full release here: https://www.businesswire.

      7/22/21 4:31:00 PM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • Covetrus Introduces New Roles and Leadership Within Its North America & Global Businesses

      New appointments bring expertise to further advance the Company's strategic plan, synchronize the Company's global capabilities and drive operational excellence Covetrus® (NASDAQ:CVET), a global leader in animal-health technology and services, announced the appointments of Bekki Kidd and András Bolcskei to the roles of head of North America Operations & Global Operational Excellence and president of International, respectively. Both roles are new for the Company and in alignment with Covetrus' strategic plan to drive synchronization and optimization of the business. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210628005245/en/

      6/28/21 8:30:00 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • Covetrus Appoints Paul Fonteyne to its Board of Directors

      Fonteyne, former CEO of Boehringer-Ingelheim USA, brings 30+ years of pharmaceutical and animal healthcare experience to the Covetrus board Covetrus® (NASDAQ:CVET), a global leader in animal-health technology and services, announced the appointment of Paul Fonteyne to its Board of Directors, bringing the number of directors to eleven. Mr. Fonteyne's deep pharmaceutical industry experience in both human and animal health markets will benefit the company as Covetrus continues its transformation and drives its mission to deliver better care and outcomes within the veterinary industry. "Paul's wealth of executive leadership experience and deep expertise in animal health makes him an ideal and

      5/18/21 8:30:00 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • Covetrus Appoints North American Chief Veterinary Officer

      PORTLAND, Maine--(BUSINESS WIRE)--Covetrus (NASDAQ: CVET), a global leader in animal-health technology and services, today announced the appointment of Link Welborn, DVM, DABVP as Covetrus’ chief veterinary officer (CVO) in North America. In his role, Dr. Welborn will champion the role of the veterinarian in providing better care for animals, while counseling Covetrus on ways to deliver better business outcomes for veterinary practices. Dr. Welborn will also work collaboratively with Dr. Rens van Dobbenburgh, Covetrus’ CVO in Europe as the Company leverages its global footprint for the betterment of the veterinary community. “We’ve placed our bet on the veterinarian, which is wh

      2/24/21 8:00:00 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • Covetrus Announces First-Ever Chief Consumer Officer

      PORTLAND, Maine--(BUSINESS WIRE)--Covetrus (NASDAQ: CVET), a global leader in animal-health technology and services, today announced the appointment of Deborah Sharkey as chief consumer officer (CCO). In this first-of-its-kind role for the company, Deborah will be responsible for developing innovative solutions that support and strengthen the relationship between veterinarian and pet owner. “Like all modern consumers, pet owners desire convenience coupled with seamless delivery of products and services,” said Ben Wolin, Covetrus president and CEO. “With her dual background in e-commerce and consumer experience, Deborah will be instrumental in our mission to empower veterinarians

      2/22/21 4:15:00 PM ET
      $CVET
      Other Pharmaceuticals
      Health Care

    Covetrus Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Semrush Strengthens Customer Focus with Appointment of Veronique Montreuil as Chief Customer and Data Officer

      Semrush (NYSE:SEMR), a leading online visibility management SaaS platform, is pleased to announce that Veronique Montreuil joins the executive team as Chief Customer and Data Officer. With over 20 years of experience in customer success and customer experience, Veronique brings a wealth of expertise to enhance customer relationships and drive growth. In her most recent role as Head of Technology Sales and Customer Success at Covetrus (NASDAQ:CVET), Veronique led a team of 275 professionals, driving operational efficiency, fostering deep customer relationships, and optimizing customer value through strategic initiatives and process improvements. She held prior roles at companies INAP (NASD

      8/8/24 9:00:00 AM ET
      $SEMR
      $CVET
      Computer Software: Prepackaged Software
      Technology
      Other Pharmaceuticals
      Health Care
    • Westlake Set to Join S&P MidCap 400; MillerKnoll to Join S&P SmallCap 600

      NEW YORK, Oct. 13, 2022 /PRNewswire/ -- Westlake Corp. (NYSE:WLK) will replace MillerKnoll Inc. (NASD:MLKN) in the S&P MidCap 400, and MillerKnoll will replace Covetrus Inc. (NASD:CVET) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, October 18. Clayton, Dubilier & Rice and TPG Capital acquired Covetrus in a deal that closed today. MillerKnoll is more representative of the small-cap market space. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector October 18, 2022 S&P MidCap 400 Addition Westlake WLK Materials S&P MidCap 400 Deletion Miller

      10/13/22 5:50:00 PM ET
      $CVET
      $MLKN
      $SPGI
      $WLK
      Other Pharmaceuticals
      Health Care
      Office Equipment/Supplies/Services
      Consumer Discretionary
    • Covetrus Names Michelle Bonfilio as Chief People Officer

      Covetrus® (NASDAQ:CVET), a global leader in animal-health technology and services, today announced the appointment of Michelle Bonfilio as Chief People Officer, reporting to Ben Wolin, President and Chief Executive Officer at Covetrus. In this role, Bonfilio will oversee the human resources and communications organizations and help shape the culture of the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220926005710/en/Michelle Bonfilio (Photo: Business Wire) "Michelle has a proven track record of empowering teams to achieve results, driving an inclusive culture and aligning purpose to the work employees do each day," sai

      9/26/22 4:00:00 PM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • Covetrus Names Margie B. Pritchard General Counsel

      Covetrus® (NASDAQ:CVET), a global leader in animal-health technology and services, today announced the appointment of Margie B. Pritchard as General Counsel and Corporate Secretary, reporting to Ben Wolin, President and Chief Executive Officer (CEO) at Covetrus. Prior to being named as General Counsel, Pritchard most recently served as Vice President, Deputy Counsel at Covetrus, where she was responsible for corporate and board governance, public reporting, advising investor relations, employment matters including compensation, and providing general legal counsel to executive management. "Margie has been serving as Interim General Counsel since December 2021, and we are thrilled to have h

      8/26/22 8:00:00 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • Covetrus Announces Retirement of Matthew Foulston

      Covetrus® (NASDAQ:CVET), a global leader in animal-health technology and services, today announced that Matthew Foulston, the Company's Executive Vice President and Chief Financial Officer, has informed the company that he will be retiring from the company effective December 31, 2022. Foulston's role at Covetrus caps off a strong career in which he has led technical, strategic and operational finance teams within a broad range of manufacturing, distribution and automotive companies. Since joining Covetrus in 2020, Foulston's leadership and depth of experience served the company well. "Matthew is a strong financial partner to our business, our leadership, our Board, and me. Plus, he's a gre

      8/11/22 4:05:00 PM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • Covetrus Announces Financial Results for Second Quarter of 2022

      Second quarter 2022 net sales of $1.22 billion, an increase of 2% year-over-year; GAAP net loss attributable to Covetrus of $(4) million Non-GAAP organic net sales growth of 5% year-over-year Non-GAAP adjusted EBITDA was flat year-over-year at $66 million, including a $2 million year-over-year headwind from the strengthening of the U.S. Dollar First half 2022 net sales of $2.37 billion, an increase of 3% year-over-year; GAAP net loss attributable to Covetrus of $(6) million Non-GAAP organic net sales growth of 6% year-over-year Non-GAAP adjusted EBITDA increased 5% year-over-year to $129 million, including a $4 million year-over-year headwind from the strengthening of the U.S.

      8/4/22 8:00:00 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • Covetrus Announces Second Quarter 2022 Earnings Release Date

      Covetrus® (NASDAQ:CVET), a global leader in animal-health technology and services, announced today that it will release second quarter 2022 results before the markets open on Thursday, August 4, 2022. As a result of the Company's previously announced agreement to be acquired by Clayton, Dubilier & Rice and TPG, Covetrus will not conduct a quarterly earnings call to discuss second quarter results with the financial community. About Covetrus Covetrus is a global animal-health technology and services company dedicated to empowering veterinary practice partners to drive improved health and financial outcomes. We are bringing together products, services, and technology into a single platform

      7/28/22 8:00:00 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • Study Reveals New Covetrus Technology Saves Time, Provides Relief to Overworked, Understaffed Veterinary Practices

      Veterinary survey respondents in North America report that Covetrus Pulse is simple to use and saves time amid worker shortages and burnout. Covetrus Pulse™ saves time and is easy to implement, finds a new customer survey by Covetrus® (NASDAQ:CVET), a global leader in animal-health technology and services. Among survey respondents reporting time savings, Pulse saved an average of 3 hours per work week. Practice managers who reported gains said Pulse saved them an average of 45 minutes daily. The cumulative effect of this time saved results in a more efficient and profitable practice. Covetrus surveyed 2,500 practices in North America that have used Pulse since January 2022 to learn about

      7/26/22 8:00:00 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • Covetrus to Be Acquired by Clayton, Dubilier & Rice and TPG at an Enterprise Valuation of Approximately $4 Billion

      Covetrus Shareholders to Receive $21.00 per Share in Cash Represents a 39% premium to Covetrus' unaffected 30-day VWAP as of May 13, 2022 Covetrus® (NASDAQ:CVET) ("Covetrus" or the "Company"), a global leader in animal-health technology and services, today announced that it has entered into a definitive agreement pursuant to which funds affiliated with Clayton, Dubilier & Rice ("CD&R"), a global private investment firm, and TPG Capital, the private equity platform of global alternative asset management firm TPG ("TPG"), will acquire all outstanding shares of Covetrus common stock not already owned by affiliates of CD&R for $21.00 per share in cash, representing an enterprise value of appr

      5/25/22 8:20:00 AM ET
      $CVET
      Other Pharmaceuticals
      Health Care
    • Covetrus Introduces Innovative Cloud-Based Practice Management Software for Veterinarians in the United Kingdom, EMEA and Asia Pacific

      Covetrus Ascend builds on existing technology portfolio with addition of comprehensive functionality without the constraints of a traditional hardware system. Covetrus® (NASDAQ:CVET), a global leader in animal-health technology and services, today introduced Ascend—a powerful, cloud-based Practice Management software (PMS) built to enable veterinary practices across the United Kingdom, EMEA and Asia Pacific. Ascend improves efficiency, streamlines internal communication and collaboration, and creates a better experience for staff and clients. In today's high-demand environment, the introduction of Ascend addresses a clear and spoken technological need amongst the veterinary community. In

      5/5/22 4:01:00 PM ET
      $CVET
      Other Pharmaceuticals
      Health Care